Akso Health
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Its last 6 Sell calls were followed by a 3% average decline over the next quarter.
- Recent price momentum is +2.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 1.6% | Better than 33% |
| Net income CAGR (3Y) | 16.1% | Better than 68% |
| Free cash flow CAGR (3Y) | -48.8% | Better than 5% |
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | -0.1% | Better than 2% |
| Operating margin | -28.9% | Better than 11% |
| Net margin | -135.0% | Better than 6% |
| Return on equity | -9.8% | Better than 20% |
| Return on invested capital | -9.8% | Better than 18% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 35.5% | Better than 99% |
| 6-month return | -17.6% | Better than 30% |
| 12-month return (ex latest month) | -21.2% | Better than 14% |
| Distance below 52-week high | 49.6% | Better than 19% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 21.8x | Better than 98% |
| Debt to assets | 0.2% | Better than 98% |
| Interest coverage | -19.8x | Better than 10% |
| Free cash flow / net income | 133.3% | Better than 59% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 1.28
- Open
- 1.30
- Day range
- 1.24 - 1.30
- Avg price
- 1.26
- Volume
- 8.56K
- Turnover
- 10.78K
- Turnover ratei
- 0.00%
- Volume ratioi
- 3.38
- Amplitudei
- 4.69%
- 52-week rangei
- 0.68 - 2.50
Valuation
- P/Ei
- -42.00
- P/E (TTM)i
- -42.00
- P/Bi
- 5.97
- EPSi
- -0.03
- Book value / shi
- 0.21
- Net profit
- -25.70M
- Net assets
- 180.76M
Share structure
- Market cap
- 1.08B
- Float capi
- 1.08B
- Shares out
- 856.70M
- Float sharesi
- 856.70M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
49.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-60.93K net over the window
Short interest
- Shares short
- 62.36K
- % of floati
- 0.01%
- Days to coveri
- 3.92
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Akso Health (AHG)?
Akso Health last traded at 1.26. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Akso Health's market cap?
About 1.08B.
What is the P/E ratio of Akso Health?
The trailing twelve-month P/E is -42.00. The Valuation tab shows it against the stock's own five-year range.
Does Akso Health pay a dividend?
Akso Health does not currently pay a regular dividend.
What is Akso Health's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Akso Health a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Akso Health discussion 0 comments